Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia
F. Barneh, J. B. Koedijk, N. E. Wijnen, T. Meulendijks, M. Ashtiani, E. Dunnebach, N. Dautzenberg, A. M. Cornel, A. Krippner-Heidenreich, K. Klein, C. M. Zwaan, J. Kuball, S. Nierkens, J. Cloos, G. J. L. Kaspers, O. Heidenreich
This study evaluates CD19 expression in pediatric AML and shows that CD19-directed immunotherapies are effective against CD19+ AML, similar to their efficacy in BCP-ALL.
bioRxiv · Apr 19, 2024Immunology